Investor Service Announcement no. 3/2010

To: NASDAQ OMX Copenhagen Hørsholm, Denmark, August 13, 2010


LifeCycle Pharma A/S to Host Conference Call Announcing Interim Report for
2nd Quarter 2010 - results from April 1 to June 30, 2010

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 2nd
Quarter 2010 on Wednesday August 18, 2010 after 05:00 PM. LCP's Executive
Management will host an accompanying conference call to discuss the financial
results on Wednesday August 18, 2010 at 05:30 PM CET (Denmark); 04:30 GMT
(London), 11:30 AM ET (New York), 08:30 AM PT (San Francisco).

To access the live conference call, please dial one of the following numbers:

+45 32 71 35 00 Denmark
+44 (0)20 7138 0844 UK
+1 212 444 0896 USA
Access code 1264445

A call audio replay of the conference will be available on www.lcpharma.com
from Thursday, August 19, 2010 at 18:00 CET (Denmark); 17:00 GMT (London),
12:00 PM ET (New York), 09:00 AM PT (San Francisco), through Friday, September
10, 2010 by dialing +45 32 71 09 13 (DK), +44 (0) 20 7111 1244 (UK) or +1 347
366 9565 (US), and entering access code 2534991#.

For more information, please contact:

Dr. William J. Polvino
President & Chief Executive Officer
Phone: + 45 7033 3300
Email: [email protected]

or

Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: [email protected]


About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market, but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide®, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.

18082010 - lifecycle pharma to host interim report q2 2010 call .pdf